

Investor call – 9:00am AWST Wednesday 1 April 2020

30 March 2020: PYC Therapeutics (ASX: **PYC**) ('PYC') will host an investor call for shareholders on Wednesday 1 April 2020 at 9am AWST (11am AEST). The management team of PYC will address questions on the efficacy read-outs in PYC's lead drug development program which will be announced to the Australian Securities Exchange at 10am AEST on the same day.

Please register at the link below to be assigned dial-in and viewing details:

https://zoom.us/meeting/register/uZUsc-uoqz0rfi7-jmwhhs9DH7_QpYsx-g

After registering, you will receive a confirmation email containing information about joining the meeting.

Or dial in at:

+61 2 8015 6011; or

+61 3 7018 2005; or

+61 8 7150 1149

When prompted enter meeting ID: 411-420-561

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.

ENDS For further information, please contact:

INVESTORS
Kaggen Ausma
CBO
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company solving a major challenge in the development of a revolutionary new class of drugs – delivering large drugs into cells. Cell Penetrating Peptides (CPPs) can overcome ‘the delivery challenge’ and provide access for a wide range of potent and precise drug ‘cargoes’ to the ‘undruggable genome’ – the highest value drug targets that exist inside cells. PYC Therapeutics is using its CPP platform to develop a pipeline of novel therapies with an initial focus on inherited retinal diseases.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company’s control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company’s current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics

ACN 098 391 961